06 November 2024
EMA/CAT/514663/2024
Human Medicines Division

Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 06-08 November 2024

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

06 November 2024, 14:00 – 18:30

07 November 2024, 09:00 – 18:30

08 November 2024, 09:00 – 13:00

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 06-08 November 2024. See November 2024 CAT minutes (to be published post December 2024 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 06-08 November 2024 meeting

1.3. Adoption of the minutes

CAT minutes for 09-12 October 2024 meeting

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

2.5.1. Lifileucel - EMEA/H/C/004741

Treatment of unresectable or metastatic melanoma

Scope: Day 80 assessment report

Action: for information

2.6. Update on ongoing initial applications

No items

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0043/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli, PRAC Rapporteur: Gabriele Maurer

Scope: Safety & Quality, request for supplementary information

A grouped application consisting of:

C.I.6 (Type II): Extension of indication for Breyanzi to include treatment of adult patients with 3rd line + follicular lymphoma (FL) based on final results from the pivotal study JCAR017-FOL-001 (FOL-001, TRANSCEND-FL). This is a phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with relapsed or refractory (r/r) follicular Lymphoma (FL) or marginal zone lymphoma (MZL). As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.0 of the RMP is being submitted. Furthermore, as part of the application the MAH is requesting a 1-year extension of the market protection.

B.II.d.1.e (Type II)

B.II.d.1.a (Type IB)

B.II.d.1.a (Type IB)

Action: for adoption

2.11.2. Ebvallo - Tabelecleucel - Orphan - EMEA/H/C/004577/II/0011/G

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Quality, request for supplementary information

Action: for adoption

Request for supplementary information adopted on 13.09.2024.

2.11.3. Hemgenix - Etranacogene dezaparvovec - Orphan - EMEA/H/C/004827/II/0018

CSL Behring GmbH

Rapporteur: Silke Dorner

Scope: Clinical

Update of sections 4.4 and 5.1 of the SmPC in order to reflect a modified 9-point anti-AAV5 Neutralising Antibody (NAb) assay. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information (PI) and update the list of local representatives in the Package Leaflet and bring the PI in line with the QRD version 10.4.

Action: for adoption

2.11.4. Libmeldy - Atidarsagene autotemcel - Orphan - EMEA/H/C/005321/II/0031/G

Orchard Therapeutics (Netherlands) B.V.

Rapporteur: Emmely de Vries

Scope: Quality, request for supplementary information

Action: for adoption

2.11.5. ROCTAVIAN - Valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/II/0014

BioMarin International Limited

Rapporteur: Violaine Closson Carella, PRAC Rapporteur: Bianca Mulder

Scope: Clinical

Update of the Annex II in order to propose changes to the current marketing authorisation obligations for ROCTAVIAN. The RMP version 1.3 has also been submitted.

Action: for adoption

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Abecma - Idecabtagene vicleucel - Orphan - EMEA/H/C/004662/REC/022.1

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeken

Scope: Clinical

Amended Protocol
Recommendation #19: The MAH should submit, within a time period of two months, a draft protocol and statistical analysis plan (SAP) for a prospective observational study assessing whether potentially suboptimal bridging therapy in high-risk patients observed in the KarMMa-3 study may be alleviated in a real-world setting. This draft should then be discussed with CAT/CHMP, so that a decision can be made on whether such a prospective study should be initiated, in its initial or amended form.

Action: for adoption

2.13.2. Casgevy - Exagamglogene autotemcel - Orphan - EMEA/H/C/005763/MEA/011

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical & Pharmacovigilance, request for supplementary information

Protocol v. 1.0 / Study no VX24-290-102
Title: Healthcare Professional Survey (HCP) to Assess the Effectiveness of the Additional Risk Minimization Measures (aRMM) for Casgevy® (exagamglogene autotemcel)

Action: for adoption

2.13.3. Tecartus - Brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/ANX/002.5

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical & Pharmacovigilance, request for supplementary information

MAH's response to ANX 002.2 [PAES Statistical Analysis and PASS Study KTE-EU-472-6036] RSI as adopted in February 2022. amendment #4. Title: Long-term, non-interventional study of recipients of Tecartus (brexucabtagene autoleucel) for treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (MCL).

In order to further characterise the long-term efficacy and safety of Tecartus in adult patients with relapsed or refractory MCL, the MAH shall conduct and submit the results of a prospective study based on data from a registry, according to an agreed protocol.

Action: for adoption

2.13.4. Tecartus - Brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/R/0047

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Rune Kjeken, PRAC Rapporteur: Bianca Mulder

Scope: 1 year renewal of marketing authorisation

Action: for adoption

Request for supplementary information adopted on 13.09.2024.

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

Deadline for submission of new requests: 24.10.2024. New requests will appear in version 1 of the agenda.

Timetable:

-Start of the procedure:	25.11.2024
-EMA Coordinator's draft report:	19.11.2024
-CAT Coordinator's comments:	27.11.2024
-Revised scientific recommendation:	29.11.2024
-CAT's discussion of scientific recommendation:	06.12.2024

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Autologous primary urothelial cells expanded

Cystoplasty/orthotopic neobladder

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.2. Adeno-associated virus serotype 5 containing the human NR2E3 gene (AAV5-hNR2E3)

Treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy, specifically retinitis pigmentosa or Leber congenital amaurosis, and who have sufficient viable retinal cells

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.3. CD70 CAR+, TCRαβ− viable cells

Treatment of renal cell carcinoma

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.2. Day 30 ATMP scientific recommendation

4.2.1. Allogeneic CD19(4G7)CAR+_TCRαβ−_CD52+/− cells

Treatment of CD19-expressing hematologic malignancies

Scope: ATMP scientific recommendation

Action: for adoption

4.2.2. Autologous adult bone marrow-derived, non-expanded CD133+ haematopoietic stem cells

Treatment of Asherman's syndrome

Scope: ATMP scientific recommendation

Action: for adoption

4.2.3. Chimeric group B adenovirus from parental wildtype viruses Ad3 and Ad7 with attenuation in E3 region and no inserted sequences

Treatment of ovarian cancer

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Human allogeneic cardiosphere-derived cells

Treatment of muscular dystrophy

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

4.4.2. Allogenic fibroblasts embedded in a scaffold of hyaluronic acid and fibrinogen

Treatment of chronic and refractory ulcers

Scope: European Commission raised comments. ATMP scientific recommendation

Action: for discussion

4.4.3. hiPSC derived Ovarian Support Cells (OSCs)

For ex vivo maturation of human oocytes

Scope: European Commission raised comments. ATMP scientific recommendation

Action: for discussion

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	28-31.10.2024
- Appointment of CAT Peer Reviewers:	06-08.11.2024
- SAWP first reports:	18.11.2024
- CAT Peer Reviewer comments (NC/C):	22.11.2024
- CAT Peer Reviewer comments (Q):	27.11.2024
- Discussion at SAWP:	25-28.11.2024
- Discussion at CAT and feedback to SAWP:	04-06.12.2024

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	25-28.11.2024
- Appointment of CAT Peer Reviewers:	04-06.12.2024
- SAWP first reports:	06.01.2025
- CAT Peer Reviewer comments (NC/C):	10.01.2025
- CAT Peer Reviewer comments (Q):	15.01.2025
- Discussion at SAWP:	13-16.01.2025
- Discussion at CAT and feedback to SAWP:	22-24.01.2025

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start:	28-31.10.2024
SAWP recommendation:	16.01.2025
CAT recommendation:	24.01.25
CHMP adoption of report and final recommendation:	30.01.2025

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

7.1.2. CAT Strategic Review & Learning meeting (SRLM) under the Hungarian presidency – 19-20 November 2024

CAT: Andras Donaszi-Ivanov, Viola Bardóczy

Scope: Final agenda of the upcoming SRLM

Action: for discussion

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

7.5.1. CoGenT Pilot

Scope: To provide an update and seek feedback on proposed touchpoints / exchange of

information for the selected procedures.

Action: for discussion

7.5.2. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Ilona Reischl

Scope: Verbal report from the teleconference of 19.09.2024

Action: for information

7.6. CAT work plan

7.6.1. CAT symposium – 10.10.2024, Amsterdam, the Netherlands

Scope: Feedback from the symposium

Action: for information

7.6.2. CAT work plan 2025

CAT: Ilona Reischl

Scope: Work plan topics in the draft 2025 CAT workplan

Action: for discussion

7.7. Planning and reporting

No items

7.8. Others

7.8.1. CAT regulatory session at the ESGCT Annual meeting (25.10.2024)

CAT: Ilona Reischl, Kieran Breen, Emmely de Vries

Scope: Verbal feedback from the CAT regulatory session

Action: for information

7.8.2. Unauthorised Dendritic cell therapies

CAT: Joseph De Courcey, Ilona Reischl

Scope: Exchange on national investigations of the involved companies

Action: for discussion

7.8.3. FDA – Cell therapy CMC readiness for late-stage INDs

CAT: Ilona Reischl

Scope: Transcript from the FDA CBER OTP Town Hall meeting of 5 September 2024

Action: for information

8. Any other business

No items

Date of next CAT meeting:

06-08 December 2024

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:

List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA's regulatory activities

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/